To hear about similar clinical trials, please enter your email below
Trial Title:
Investigating Participation Patterns Among Stage IV Melanoma Patients
NCT ID:
NCT06093594
Condition:
Stage IV Melanoma
Conditions: Official terms:
Melanoma
Conditions: Keywords:
Stage IV Melanoma
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Summary:
Clinical trials, specifically focused on stage IV melanoma, are crucial in assessing the
safety and efficacy of new treatments for this disease. These trials serve as fundamental
instruments in determining whether emerging medications outperform standard therapies,
providing compelling evidence to support wider implementation.
The main goal is to thoroughly scrutinize trial completion rates and voluntary
withdrawals among this particular group of patients.
Criteria for eligibility:
Study pop:
Patients with stage IV melanoma who are actively considering enrolling in a clinical
study for said condition, but have not yet completed enrollment and randomization.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Aged ≥ 18 years old
- Diagnosis of stage IV melanoma
- Able to comprehend the investigational nature of the protocol and provide informed
consent
Exclusion Criteria:
- Female patients who are currently pregnant or nursing
- Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
- Inability to perform regular electronic reporting
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Power Life Sciences
Address:
City:
San Francisco
Zip:
94107
Country:
United States
Contact:
Last name:
Michael B Gill
Phone:
415-900-4227
Email:
https://www.withpower.com/contact-us@withpower.com
Start date:
November 2024
Completion date:
November 2026
Lead sponsor:
Agency:
Power Life Sciences Inc.
Agency class:
Industry
Source:
Power Life Sciences Inc.
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06093594
